# US 2012/0251559 A1 · Treatment of B-Cell Cancers With Anti-CD70 Antibody-Drug Conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251559 A1
- Document ID: US20120251559A1
- Status: Published application
- Kind: A1
- Application number: 13/491,475
- Filed: 2012-06-07
- Published: 2012-10-04
- Earliest claimed: 2003-02-20
- Assignees: Seattle Genetics, Inc.
- Inventors: Che-Leung Law; Alan F. Wahl; Nathalie Scholler; Linda A. Pestano
- Web page: https://patentgrep.com/patent/US20120251559A1

## CPC

- A61K 49/0041: {Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 49/0058: {Antibodies}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/06: for tuberculosis
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of a CD70-expressing cancer, comprising administering to a subject the disclosed pharmaceutical compositions.

## Claims

### Claim 1

A method for the treatment of a CD70-expressing cancer of a B-cell lineage in a human subject, the method comprising:
administering to the subject, in an amount effective for the treatment thereof, an antibody-drug conjugate comprising an antibody that specifically binds to CD70, wherein:
(i) the drug is a cytotoxic agent, and
(ii) the antibody-drug conjugate is internalized into cells, where it exerts a therapeutic effect.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody is a humanized antibody.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody is a chimeric antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is multivalent.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cytotoxic agent is selected from the group consisting of an auristatin, a DNA minor groove binding agent, a DNA minor groove alkylating agent, an enediyne, a duocarmycin, a maytansinoid, and a vinca alkaloid.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cytotoxic agent is an anti-tubulin agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cytotoxic agent is AFP or MMAE.

### Claim 8 (depends on 1)

The method of claim 1, wherein the antibody is conjugated to the cytotoxic agent via a linker.

### Claim 9 (depends on 8)

The method of claim 8, wherein the linker is cleavable under intracellular conditions.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cleavable linker is cleavable by an intracellular protease.

### Claim 11 (depends on 10)

The method of claim 10, wherein the linker comprises a dipeptide.

### Claim 12 (depends on 11)

The method of claim 11, wherein the dipeptide is val-cit or phe-lys.

### Claim 13 (depends on 9)

The method of claim 9, wherein the cleavable linker is hydrolyzable at a pH of less than 5.5.

### Claim 14 (depends on 13)

The method of claim 13, wherein the hydrolyzable linker is a hydrazone linker.

### Claim 15 (depends on 9)

The method of claim 9, wherein the cleavable linker is a disulfide linker.

### Claim 16 (depends on 1)

The method of claim 1, wherein the antibody blocks binding of CD70 to CD27.

### Claim 17 (depends on 1)

The method of claim 1, wherein the antibody is a mouse antibody comprising a heavy chain variable region having the amino acid sequence set forth in residues 20 to 137 of SEQ ID NO:2, and a light chain variable region having the amino acid sequence set forth in residues 21 to 132 of SEQ ID NO:12, or a chimeric or humanized form of the mouse antibody.

### Claim 18 (depends on 17)

The method of claim 17, wherein the antibody comprises H1, H2, H3, L1, L2 and L3 complementarity-determining regions having, respectively, the amino acid sequences set forth in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10; SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20.

### Claim 19 (depends on 1)

The method of claim 1, wherein the antibody is a mouse antibody comprising a heavy chain variable region having the amino acid sequence set forth in residues 20 to 137 of SEQ ID NO:22, and a light chain variable region having the amino acid sequence set forth in residues 21 to 132 of SEQ ID NO:32, or a chimeric or humanized form of the mouse antibody.

### Claim 20 (depends on 19)

The method of claim 19, wherein the antibody is a humanized antibody comprising H1, H2, H3, L1, L2 and L3 complementarity-determining regions having, respectively, the amino acid sequences set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30; SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, respectively.

### Claim 21 (depends on 1)

The method of claim 1, wherein the CD70-expressing cancer is a B-cell lymphoma.

### Claim 22 (depends on 21)

The method of claim 21, wherein the B-cell lymphoma is Burkitt's lymphoma.

### Claim 23 (depends on 21)

The method of claim 21, wherein the B-cell lymphoma is a diffuse large B-cell lymphoma.

### Claim 24 (depends on 1)

The method of claim 1, wherein the CD70-expressing cancer is a B cell leukemia.

### Claim 25 (depends on 24)

The method of claim 24, wherein the B cell leukemia is chronic lymphocytic leukemia.
